New device shows promise for better sleep and less stress
NCT ID NCT07027657
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a device called BTL-699-2 in 43 adults to see if it could improve sleep quality and reduce stress. Participants received six treatments and filled out questionnaires about their sleep and stress levels. The goal was to find a non-drug way to help people sleep better and feel less stressed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
43 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \> 22 years * The minimal pre-treatment PSQI score of \>= 5 points * Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb * Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in sleep quality and reduction of stress, including non-invasive brain stimulation treatments other than the study procedure during study participation * Subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation * Willingness to comply with study instructions and to return to the clinic for the required visits * Women of child-bearing potential\* are required to use birth control measures during the whole duration of the study * If applicable, subjects will be maintained on pre-study prescribed medications at a stable therapeutic dosage for at least 2 months prior to study entry * Subject is not using any sleeping medication or is using over-the-counter pills (except Valerian and St. John's Wort) no more than 4 times a week Exclusion Criteria: * Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators * Metallic, ferromagnetic or other magnetic-sensitive implants/objects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 in (30 cm) of the therapy coil. (Examples include implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes and tattoos with metallic ink), * Drug pumps (within 12 in (30 cm) of the therapy coil) * Application in the heart area * Persons with a tendency to seizure (hypotonic, epileptic) * Ongoing anticoagulation therapy * Ongoing severe or life-threatening condition * Pulmonary insufficiency * Heart disorders * Renal insufficiency * Decompensated\* hemorrhagic conditions, blood coagulation disorders, cardiovascular diseases * Malignant tumor, benign tumor * Fever * Ongoing pregnancy * Suicidal tendencies or recent attempt to commit suicide * Concurrent use of electroconvulsive therapy or vagus nerve stimulation * Substance-induced depression or depression secondary to a general medical condition * Seasonal affective disorder * Substance abuse, obsessive compulsive disorder or post-traumatic stress disorder, major depression * Psychotic disorder including schizoaffective disorder, bipolar disease or major depression with psychotic features * Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia or movement disorders * History of increased intracranial pressure or head trauma * Nursing * Usage of prescription sleep medication, Valerian of St. John's Wort in the past 2 months * Usage of over-the-counter pills 5 or more times a week
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sleep quality are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AntiAging and Wellness
Chula Vista, California, 91914, United States
-
Kind Health Group
Encinitas, California, 92024, United States
-
Minooka Healthcare Center
Minooka, Illinois, 60447, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartwatch predict which cancer patients return to hospital?
- Can a Post-Training drink help young footballers recover and sleep better?
- Smart mask aims to measure blood oxygen through your face
- Can a glucose app that predicts lows calm diabetes fears?
- Can two weekend workouts match three weekly ones for sleep?
- A sleep program designed for latino kids aims to close the rest gap